News
NIH inventors have developed a new strategy of using Interleukin 24 (IL-24) to target the whole T-helper 17 cells (Th17) lineage and thus achieve improved efficacy in therapy of Th17-relevant autoimmune diseases such as uveitis, multiple sclerosis, rheumatoid arthritis, and Crohn’s disease. The Th17
NIH inventors are seeking a licensee or collaborator for a micro-engineered “thyroid-on-a-chip” that combines human thyroid organoids with integrated micro-vasculature to replicate the gland’s native blood flow and 3-D architecture, enabling rapid, patient-specific drug screening. This technology
Inventors at the NIH National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) are seeking a licensee or collaborator for positive allosteric modulators (PAMs) of the A 3 adenosine receptor (A 3AR), a known therapeutic target. These heterocyclic chemical compounds bind to a lipid
The “Top 10” list of best-selling gene therapies published by Genetic Engineering & Biotechnology News (GEN) in their May 2025 issue features three products based upon license agreements for technologies originating from the NIH Intramural Research Program. Featured and ranked on the GEN list are